Several tumor antigens have been investigated in small pilot or phase I clinical trials, such as interleukin 13 receptor subunit alpha 2 (IL13Rα2) [15,16,17], epidermal growth factor receptor variant III (EGFRvIII) [18,19], human epidermal growth factor receptor 2 (HER2) [20], erythropoietin-producing hepatocellular carcinoma A2 receptor (EphA2), and disialoganglioside 2 (GD2) [21]. This evidence concerns the gene EPO and neoplasm.